Switch theme
Sign up to access all valuation multiples
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
1995
19
Last FY Revenue n/a
Last FY EBITDA -$17.4M
$114M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, TuHURA Biosciences achieved revenue of n/a and an EBITDA of -$17.4M.
TuHURA Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TuHURA Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$17.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$28.5M | XXX | -$17.6M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$19.0M | XXX | -$21.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, TuHURA Biosciences's stock price is $3.
TuHURA Biosciences has current market cap of $120M, and EV of $114M.
See TuHURA Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $114M | $120M | XXX | XXX | XXX | XXX | $-5.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, TuHURA Biosciences has market cap of $120M and EV of $114M.
TuHURA Biosciences's trades at n/a EV/Revenue multiple, and -6.6x EV/EBITDA.
Equity research analysts estimate TuHURA Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TuHURA Biosciences has a P/E ratio of -6.3x.
See valuation multiples for TuHURA Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $120M | XXX | $120M | XXX | XXX | XXX |
| EV (current) | $114M | XXX | $114M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -6.6x | XXX | XXX | XXX |
| EV/EBIT | -4.0x | XXX | -6.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.3x | XXX | -5.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTuHURA Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.9M for the same period.
TuHURA Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TuHURA Biosciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TuHURA Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TuHURA Biosciences acquired XXX companies to date.
Last acquisition by TuHURA Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . TuHURA Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TuHURA Biosciences founded? | TuHURA Biosciences was founded in 1995. |
| Where is TuHURA Biosciences headquartered? | TuHURA Biosciences is headquartered in United States of America. |
| How many employees does TuHURA Biosciences have? | As of today, TuHURA Biosciences has 19 employees. |
| Who is the CEO of TuHURA Biosciences? | TuHURA Biosciences's CEO is Dr. James A. Bianco,M.D.. |
| Is TuHURA Biosciences publicy listed? | Yes, TuHURA Biosciences is a public company listed on NAS. |
| What is the stock symbol of TuHURA Biosciences? | TuHURA Biosciences trades under HURA ticker. |
| When did TuHURA Biosciences go public? | TuHURA Biosciences went public in 2024. |
| Who are competitors of TuHURA Biosciences? | Similar companies to TuHURA Biosciences include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of TuHURA Biosciences? | TuHURA Biosciences's current market cap is $120M |
| Is TuHURA Biosciences profitable? | Yes, TuHURA Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
